In a welcome move, Boston Scientific saw its Relative Strength Rating rise from 69 to 74 on Wednesday.
How To Invest In Stocks In Both Bull And Bear Markets
IBD's proprietary RS Rating measures market leadership by showing how a stock's price action over the last 52 weeks compares to that of the other stocks in our database.
Decades of market research reveals that the best-performing stocks typically have an RS Rating of over 80 as they launch their largest price moves. See if Boston Scientific can continue to show renewed price strength and clear that threshold.
Boston Scientific is trying to complete a flat base with a 108.94 buy point. See if it can break out in volume at least 40% above average.
Earnings growth decreased in the company's most recent report from 34% to 21%, but revenue rose from 21% to 23%.
The company holds the No. 3 rank among its peers in the Medical-Products industry group. Insulet is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
